Related references
Note: Only part of the references are listed.Vortioxetine: A Review of Its Use in Major Depressive Disorder
Karly P. Garnock-Jones
CNS DRUGS (2014)
Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-Analysis
Ursula Reichenpfader et al.
DRUG SAFETY (2014)
A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder
Atul R. Mahableshwarkar et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2014)
Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder
Jean-Philippe Boulenger et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2014)
A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder
A. R. Mahableshwarkar et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2014)
Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats
Ashley Wallace et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults
Roger S. McIntyre et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
Resting-state brain activation correlates with short-time antidepressant treatment outcome in drug-naive patients with major depressive disorder
Li-Juan Wang et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2014)
Antidepressant drugs and sexual dysfunction
David S. Baldwin et al.
BRITISH JOURNAL OF PSYCHIATRY (2013)
Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant
Grace Chen et al.
CLINICAL DRUG INVESTIGATION (2013)
A Randomized Trial on the Acute and Steady-State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition
E. L. Theunissen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder
Atul R. Mahableshwarkar et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Effects of vortioxetine versus paroxetine on polysomnography in man: a pharmacokinetic/pharmacodynamic study
S. Wilson et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
P.2.f.029 A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment
L. Häggström et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects
Per Stenkrona et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder
Rakesh Jain et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: A systematic review and meta-analysis
A. von Wolff et al.
JOURNAL OF AFFECTIVE DISORDERS (2013)
Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats
Arne Mork et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2013)
Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
David S. Baldwin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
In vitro effects of the multimodal antidepressant Lu AA21004 at human and rat 5-HT1A, 5-HT1B, 5-HT3 and 5-HT7 receptors, and 5-HT transporters
C. Sanchez et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States
Anthony J. Rothschild et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial
Leszek Bidzan et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)
David S. Baldwin et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder
Cornelius Katona et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2012)
A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder
Enric Alvarez et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2012)
A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder
Neven Henigsberg et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Major depressive disorder: new clinical, neurobiological, and treatment perspectives
David J. Kupfer et al.
LANCET (2012)
Identification of the Cytochrome P450 and Other Enzymes Involved in the In Vitro Oxidative Metabolism of a Novel Antidepressant, Lu AA21004
Mette G. Hvenegaard et al.
DRUG METABOLISM AND DISPOSITION (2012)
Sexual Side Effects of Pharmacological Treatment of Psychiatric Diseases
A. Serretti et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Biosynthesis and Identification of an N-Oxide/N-Glucuronide Metabolite and First Synthesis of an N-O-Glucuronide Metabolite of Lu AA21004
Henriette Kold Uldam et al.
DRUG METABOLISM AND DISPOSITION (2011)
Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
Benny Bang-Andersen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the 5-HTTLPR
Jana Strohmaier et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2011)
MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets
Ohidul Siddiqui et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2009)
The impact of analytic method on interpretation of outcomes in longitudinal clinical trials
A. Prakash et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches
Peter Lane
PHARMACEUTICAL STATISTICS (2008)
Activation of the serotonin 5-HT3 receptor in the dorsal raphe nucleus suppresses REM sleep in the rat
Jaime M. Monti et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Share Paper
